Biotech selling Briumvi, a B-cell-depleting antibody infusion for multiple sclerosis.
Biotech selling Briumvi, a B-cell-depleting antibody infusion for multiple sclerosis.
Nearly all revenue is Briumvi sold in the US to infusion centres, clinics and hospitals through specialty distributors and reimbursed by insurers. After withdrawing its earlier lymphoma drug Ukoniq in 2022, it is a one-product company.
Moat: narrow (IP / patents, installed base). Differentiated shorter-infusion anti-CD20 antibody competing for share in a crowded MS market.
Headquarters: New York, New York, United States · Founded: 1993 · Employees: 399
Size TG Therapeutics (TGTX) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $9.99B, the 766th largest of 3,085 United States companies the cockpit tracks. Shares closed at $66.12 on 18 Nov 2026.
Performance Over six months the shares gained 66.3%, against +7.3% for the median peer and -2.2% for the United States market (cap-weighted) — 2nd highest of 21 in its peer set.
Growth Revenue grew 68.8% over the last twelve months (peer median +13.3%); the operating margin is 21.5% (peer median 16.8%).
Valuation It trades at 25.2× forward earnings against a peer median of 33.1× (6th cheapest of 16).
Price implies For today's price to make sense, revenue must grow about 43% a year for seven years (Req g). Recent delivered growth is +427%, so the hurdle is -384 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 4.7 points above its cost of capital (13.9% WACC).
Next results Next results expected around 2 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $898M | $616M | $329M | $234M | $2.79M |
| Revenue growth | — | +87% | +41% | +8,290% | — |
| Gross profit | $743M | $516M | $290M | $219M | $2.00M |
| EBITDA | $194M | $125M | $42.2M | $21.1M | -$192M |
| Net income | $106M | $447M | $23.4M | $12.7M | -$198M |
| Free cash flow | $85.6M | -$25.0M | -$40.6M | -$31.4M | -$176M |
| Capital expenditure | $693,000 | $214,000 | $45,000 | $0 | $14,000 |
| Total debt | $754M | $254M | $254M | $111M | $83.1M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| TG Therapeutics TGTX | $9.99B | +66% | +69% | 21% | 25.2× | 43.0% |
| Roche RO.SW | $381B | +21% | -1% | 31% | 19.9× | 1.7% |
| Novartis NOVN.SW | $285B | +11% | -4% | 30% | 17.5× | 1.6% |
| Biogen BIIB | $37.2B | +34% | +2% | 17% | 17.1× | 10.1% |
| Sanofi SAN.PA | $114B | +13% | +15% | 27% | 9.7× | -4.8% |
| Bristol Myers Squibb BMY | $122B | +3% | +4% | 33% | 9.2× | -13.1% |
| Merck KGaA MRK.DE | $71.3B | +16% | +1% | 19% | 17.4× | 7.4% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | TGTX | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +21.2% | +5.6% | 3rd highest of 21 |
| 6-month return | +66.3% | +7.3% | 2nd highest of 21 |
| Distance from 52-week high | -2.8% | -11.2% | 6th highest of 21 |
| Revenue growth (TTM) | +68.8% | +13.3% | 3rd highest of 20 |
| Operating margin | 21.5% | 16.8% | 7th highest of 19 |
| Forward P/E | 25.2× | 33.1× | 6th cheapest of 16 |
| Growth the price implies (Req g, 7 yrs) | 43.0% | 18.7% | 2nd most demanding of 15 |
| Growth delivered (Del g) | +426.7% | +9.3% | highest of 15 |
| Hurdle (Req g minus delivered) | -383.7 pp | +9.0 pp | least demanding of 15 |
| ROIC minus cost of capital | +4.7 pp | +1.3 pp | 7th highest of 19 |
| EV / EBITDA | 52.9× | 22.6× | 2nd most expensive of 14 |
| Net debt / EBITDA | 1.3× | 0.0× | 4th most indebted of 14 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| TG Therapeutics TGTX | United States | $9.99B | +66% | +69% | 21% | 25.2× | 43.0% | +426.7% |
| Pharmaron Beijing 300759.SZ | China | $9.90B | +52% | +18% | 14% | 36.8× | n/a | n/a |
| Spyre Therapeutics SYRE | United States | $9.64B | +41% | n/a | n/a | n/a | n/a | n/a |
| Madrigal Pharmaceuticals MDGL | United States | $9.25B | -22% | +93% | -11% | 81.5× | n/a | n/a |
| H. Lundbeck A/S HLUN-A.CO | Denmark | $9.16B | +69% | +9% | 26% | n/a | -6.6% | +6.6% |
| Repligen RGEN | United States | $11.0B | +55% | +14% | 9% | 71.0× | 56.9% | +15.0% |
| Mankind Pharma MANKIND.NS | India | $11.6B | +5% | +13% | 21% | 44.4× | 28.6% | +18.1% |
| Zhangzhou Pientzehuang Pharmaceutical 600436.SS | China | $11.6B | -4% | -19% | 19% | 40.7× | 24.9% | +6.8% |
| Praxis Precision Medicines PRAX | United States | $8.53B | -9% | -100% | n/a | n/a | n/a | n/a |
| Kyowa Kirin 4151.T | Japan | $8.43B | +9% | +10% | 24% | 16.4× | -4.7% | +9.3% |
| Recordati REC.MI | Italy | $12.0B | +3% | +8% | 30% | 16.6× | 1.1% | +12.6% |
| Protagonist Therapeutics PTGX | United States | $8.30B | +26% | +164% | 59% | 1,532.5× | 17.5% | +10.0% |
| Shanghai Pharmaceuticals 2607.HK | Hong Kong | $8.25B | -7% | +9% | 3% | 6.3× | -9.7% | +7.4% |
| Rhythm Pharmaceuticals RYTM | United States | $8.25B | +31% | +61% | -67% | n/a | n/a | n/a |
| Sbp 1177.HK | Hong Kong | $12.2B | +5% | +15% | 30% | 17.5× | -5.7% | +5.4% |
| Dr. Reddy's Laboratories DRREDDY.NS | India | $12.5B | +5% | -4% | 9% | 32.0× | 30.7% | +12.1% |
| Glenmark Pharmaceuticals GLENMARK.NS | India | $7.98B | +10% | 0% | 17% | 33.1× | 27.3% | +9.4% |
| ALK-abello A/S ALK-B.CO | Denmark | $7.94B | -8% | +16% | 26% | 34.8× | 7.3% | +12.6% |
| Alkermes Public ALKS | United States | $7.87B | +27% | +15% | 5% | n/a | 32.5% | +7.3% |
| Zydus Lifesciences ZYDUSLIFE.NS | India | $12.8B | +18% | +24% | 17% | 30.0× | n/a | n/a |
| Shanghai Fosun Pharmaceutical (Group) 2196.HK | Hong Kong | $7.74B | -15% | +10% | 6% | 9.0× | 19.9% | +5.8% |